Supernus Pharmaceuticals v. Appco Pharma: Viloxazine ADHD Patent Dispute Ends in Voluntary Dismissal
What would you like to do next?
Choose your path based on your current needs in pharmaceutical IP:
In a closely watched pharmaceutical patent dispute, Supernus Pharmaceuticals, Inc. voluntarily dismissed its infringement complaint against Appco Pharma LLC without prejudice, closing case No. 1:25-cv-00807 in the U.S. District Court for the District of Delaware after just 91 days. Filed on July 1, 2025, and resolved by September 30, 2025, the case centered on six patents covering viloxazine extended-release capsules — the active ingredient in Supernus’s ADHD treatment Qelbree® — and Appco’s allegedly infringing generic versions at 100 mg, 150 mg, and 200 mg dosage strengths.
While no judgment on the merits was reached, voluntary dismissals of this nature in Hatch-Waxman litigation rarely signal defeat. They frequently reflect negotiated resolutions, strategic repositioning, or procedural recalibration. For patent attorneys, in-house counsel, and R&D leaders operating in the competitive ADHD therapeutics space, this case offers valuable insight into pharmaceutical patent litigation strategy and the dynamics of generic drug challenges under the Abbreviated New Drug Application (ANDA) framework.
📋 Case Summary
| Case Name | Supernus Pharmaceuticals, Inc. v. Appco Pharma LLC |
| Case Number | 1:25-cv-00807 (D. Del.) |
| Court | U.S. District Court for the District of Delaware |
| Judge | Judge Jennifer L. Hall (Magistrate Judge) |
| Duration | Jul 2025 – Sep 2025 3 months |
| Outcome | Voluntary Dismissal Without Prejudice |
| Plaintiff Counsel | Faegre Drinker Biddle & Reath LLP |
| Defendant Counsel | Not identified in case data |
| Patents at Issue | |
| Accused Products | Viloxazine Extended-Release Capsules (100mg, 150mg, 200mg) |
Case Overview
The Parties
⚖️ Plaintiff
Maryland-based specialty pharmaceutical company focused on central nervous system (CNS) disorders, holding FDA approval for Qelbree® (viloxazine ER capsules) for ADHD treatment.
🛡️ Defendant
Generic pharmaceutical manufacturer. Somerset Therapeutics LLC was also named as a co-defendant, indicating a collaborative generic development or commercialization arrangement.
The Patents at Issue
This landmark case involved six U.S. patents asserted, all directed to viloxazine formulation and therapeutic use technology, forming a layered IP estate:
- • US12121523B2 — Application US17/896774 (Formulation/Use)
- • US11324753B2 — Application US15/615423 (Formulation/Use)
- • US9358204B2 — Application US13/761757 (Formulation/Use)
- • US11458143B2 — Application US17/718819 (Formulation/Use)
- • US9603853B2 — Application US15/157549 (Formulation/Use)
- • US9662338B2 — Application US15/172955 (Formulation/Use)
The Accused Product
The accused product was viloxazine extended-release capsules in 100 mg, 150 mg, and 200 mg strengths — the precise dosage forms commercially available under Supernus’s Qelbree®.
Legal Representation
Supernus was represented by **Faegre Drinker Biddle & Reath LLP**, with attorneys **Edgar H. Haug**, **Francis DiGiovanni**, **Nicholas F. Giove**, and **Thatcher A. Rahmeier** listed as counsel. No defendant counsel was identified in the case data.
Litigation Timeline & Procedural History
The case followed an unusually compressed lifecycle in the U.S. District Court for the District of Delaware, a premier venue for pharmaceutical patent litigation:
- July 1, 2025: Complaint filed in the District of Delaware.
- September 30, 2025: Case closed via voluntary dismissal without prejudice.
- Total Duration: 91 days (3 months).
A 91-day resolution — before any substantive motion practice, claim construction, or discovery disputes would typically conclude — strongly suggests the dismissal reflects either an out-of-court agreement or Supernus’s strategic decision to refile.
The Verdict & Legal Analysis
Outcome
Supernus Pharmaceuticals filed a notice of voluntary dismissal without prejudice pursuant to **Federal Rule of Civil Procedure 41(a)**, effectively withdrawing its complaint against both Appco Pharma LLC and Somerset Therapeutics LLC. No damages were awarded, no injunction was entered, and no judgment on patent validity or infringement was issued. The “without prejudice” designation is legally significant: Supernus retains full rights to re-assert these six patents against these defendants in future proceedings.
Verdict Cause Analysis
The case was brought as a standard **patent infringement action** — the expected procedural vehicle in Hatch-Waxman litigation following a generic manufacturer’s ANDA filing with Paragraph IV certifications. The strategic calculus behind Rule 41(a) dismissals in ANDA litigation typically involves one or more of the following scenarios:
- Negotiated resolution: The parties reached a confidential settlement or licensing agreement.
- Strategic consolidation: Supernus may be coordinating litigation across multiple ANDA filers.
- Amendment or refiling: The dismissal may precede a refiled action with refined claim allegations.
Importantly, no adverse legal findings were made against Supernus’s patent portfolio. The six asserted patents remain in force and presumptively valid under **35 U.S.C. § 282**.
Legal Significance
The absence of a merits ruling limits this case’s direct precedential value. However, the case highlights the increasing use of layered patent portfolios — sometimes called “patent thickets” — in CNS drug litigation. Supernus’s assertion of six patents spanning nearly a decade of prosecution history signals a robust and deliberately constructed exclusivity strategy.
Developing a new drug formulation?
Learn from this case. Use AI to draft stronger claims that can withstand Hatch-Waxman litigation.
Industry & Competitive Implications
The viloxazine ADHD market is commercially significant. Qelbree® represents one of the few non-stimulant ADHD options with both pediatric and adult labeling, positioning it as a differentiated asset. Generic entry at 100 mg, 150 mg, and 200 mg strengths would directly threaten Supernus’s revenue base — making aggressive patent assertion a financially rational strategy regardless of ultimate case outcome.
The dismissal without prejudice preserves Supernus’s **30-month stay** leverage under Hatch-Waxman if litigation is reinstituted within applicable timeframes, potentially delaying Appco’s generic launch. This procedural tool remains one of the most powerful in the branded pharmaceutical litigation arsenal.
More broadly, this case reflects an industry-wide trend: branded CNS manufacturers are filing earlier, broader patent portfolios and litigating assertively even when resolution occurs pre-trial. For companies developing generic CNS products, the cost of early Paragraph IV challenges — particularly against multi-patent estates in Delaware — must be weighed carefully against time-to-market objectives.
Power Your Pharmaceutical IP Strategy with PatSnap Eureka IP
From novelty searches to patent drafting, PatSnap Eureka’s AI-powered tools help you navigate the complex pharma patent landscape with confidence.
⚠️ Freedom to Operate (FTO) Analysis
This case highlights critical IP risks in pharmaceutical product development. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this litigation for viloxazine and similar ADHD treatments.
- View all 6 asserted patents in detail
- See which companies are most active in CNS patents
- Understand formulation and method-of-use claim patterns
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own drug formulation or therapeutic product.
- Input your drug description or technical features
- AI identifies potentially blocking patents
- Get actionable infringement risk assessment report
High Risk Area
Viloxazine ER formulations & therapeutic uses
6 Asserted Patents
Covering formulation and use
ANDA Strategy Insights
From this dismissal without prejudice
✅ Key Takeaways
For Patent Attorneys & Litigators
Voluntary dismissal without prejudice under Rule 41(a) preserves full re-assertion rights — treat it as a strategic tool, not a concession.
Search related case law →Multi-defendant complaints (including distributors like Somerset Therapeutics) are increasingly standard in Hatch-Waxman strategy.
Explore Hatch-Waxman strategy →Six-patent assertion portfolios in a single ANDA case reflect the growing complexity of pharmaceutical IP estates requiring sophisticated defense coordination.
Analyze pharma patent thickets →For IP Professionals
Monitor Supernus’s patent portfolio activity (US12121523B2 through US9662338B2) for continuation filings or reissue proceedings.
Track patent family changes →The absence of defendant counsel in court records may indicate early-stage settlement negotiations occurred outside formal litigation channels.
Understand settlement trends →For R&D Leaders
Extended-release CNS formulations face layered patent risks; FTO analyses must account for method-of-treatment, dosage form, and formulation patents independently.
Start FTO analysis for my product →Generic development timelines for established CNS products like viloxazine should include a realistic litigation reserve period of 18–30 months.
Evaluate generic launch risks →Frequently Asked Questions
What patents were involved in Supernus Pharmaceuticals v. Appco Pharma?
Six U.S. patents were asserted: US12121523B2, US11324753B2, US9358204B2, US11458143B2, US9603853B2, and US9662338B2 — all covering aspects of viloxazine extended-release formulations.
Why did Supernus voluntarily dismiss the case?
The dismissal was filed without prejudice under FRCP 41(a), preserving Supernus’s right to refile. The specific reason was not disclosed; common explanations include negotiated settlement, authorized generic agreements, or strategic litigation sequencing.
How does this affect viloxazine ADHD patent litigation broadly?
No merits ruling was issued, so the validity and enforceability of Supernus’s six-patent estate remain unresolved. Future ANDA challengers for viloxazine ER products will still face this substantial patent portfolio.
Ready to Strengthen Your Pharmaceutical IP Strategy?
Join thousands of IP professionals using PatSnap Eureka to conduct prior art searches, draft patents, and analyze competitive landscapes in the pharma sector.